Skip to main content
Premium Trial:

Request an Annual Quote

Virogenomics and OHSU Receive $100K NIH Grant

NEW YORK, May 30 - NIH has awarded Virogenomics and Oregon Health & Science a phase I Small Business Technology Transfer grant to develop new anti-HIV drugs.


The $99,808 grant from the National Institute of Allergy and Infectious Diseases will be used to continue Virogenomics-sponsored research by OHSU scientists.


The researchers aim to identify novel cellular drug targets by gene expression profiling and validate them through target-specific gene silencing techniques developed by Virogenomics and OHSU.


Virogenomics, an OHSU spinoff based in Portland, Ore., was founded in 2001.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.